Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia
- PMID: 884687
Item in Clipboard
Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia
Cancer Res.
1977 Sep.
Abstract
Two congeners of cis-platinum diamminodichloride, 1,2-diamminocyclohexylplatinum malonate (NSC 224964) and 1,2-cyclohexyldiamminoplatinum sulfate (NSC 250427), show approximately equal inhibitory activity in vitro against leukemia L1210 and a line of L1210 (L1210/PDD) that has developed resistance to cis-platinum diamminodichloride. These compounds are also active against L1210/PDD in vivo. These observations suggest that they be tried clinically in patients whose disease has become resistant to cis-platinum diamminodichloride.
Similar articles
-
Synergistic effects of the combination of cis-platinum diamminodichloride and 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in transplanted mouse leukemias.Cancer Res. 1977 Nov;37(11):4098-100. Cancer Res. 1977. PMID: 71204
-
Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.Anticancer Drug Des. 1994 Dec;9(6):495-509. Anticancer Drug Des. 1994. PMID: 7880375
-
DNA synthesis, protein synthesis and platinum content following drug administration in cis-diamminedichloroplatinum(II) -sensitive and -resistant L1210 cells transferred from in vitro to in vivo conditions.Neoplasma. 1987;34(6):721-6. Neoplasma. 1987. PMID: 3431611
-
Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.Anticancer Res. 1996 Jan-Feb;16(1):33-8. Anticancer Res. 1996. PMID: 8615631
-
Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.Anticancer Drug Des. 1994 Apr;9(2):139-51. Anticancer Drug Des. 1994. PMID: 8166929
Cited by
-
New cancer chemotherapy drugs in Europe.Cancer Chemother Pharmacol. 1978;1(1):5-13. doi: 10.1007/BF00253141. Cancer Chemother Pharmacol. 1978. PMID: 373907 Review. No abstract available.
-
A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration.Cancer Chemother Pharmacol. 1995;36(6):451-8. doi: 10.1007/BF00685793. Cancer Chemother Pharmacol. 1995. PMID: 7554035 Clinical Trial.
-
Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin.Br J Cancer. 1997;76(4):502-10. doi: 10.1038/bjc.1997.416. Br J Cancer. 1997. PMID: 9275028 Free PMC article.
-
Structure-antitumor activity relationship for new analogs of thecis-dichloro(l,2-diamino cyclohexane) platinum(II) complex.Biol Trace Elem Res. 1983 Dec;5(6):517-28. doi: 10.1007/BF02988943. Biol Trace Elem Res. 1983. PMID: 24263671
-
Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.Cancer Chemother Pharmacol. 1995;35(5):441-5. doi: 10.1007/s002800050260. Cancer Chemother Pharmacol. 1995. PMID: 7850928